Expert Financial Analysis and Reporting

Investment Background and Company Overview I think that Repligen’s (RGEN) bioprocessing business is one of the best business models that I have seen in my many years as an analyst. Its products are used in the manufacturing of biologic drugs; they enjoy incredibly long life cycles because changing the manufacturing process for a biological product […]

Investment Thesis I published an extensive report on Derma Sciences (DSCI) on January 31, 2014 in which I recommended purchase. I argued in that report that DSCI presents an unusual and attractive biotechnology investment situation. We are all aware of the binary outcomes of critical phase 3 trials in which a successful outcome usually leads […]

Overview Northwest Biotherapeutics CEO Linda Powers made a presentation yesterday in which she addressed the bear case that has resulted in significant pressure on the stock in the last two weeks in particular and for the last two years in general. In my opinion, she effectively debunked a weak bear argument, but you be the […]

Recent Price Behavior Antares’ (ATRS) price has drifted down since the approval of Otrexup for the treatment of rheumatoid arthritis and psoriasis on October 14, 2013. Antares launched Otrexup on January 15, 2014 for the treatment of rheumatoid arthritis and on March 3, 2014, its partner LEO launched Otrexup for psoriasis. Last October, the price […]

Agenus (AGEN) and GlaxoSmithKline (GSK) announced that the MAGRIT phase 3 study of GSK’s MAGE-A3 cancer vaccine in non-small cell lung failed to hit the primary endpoint of progression free survival and the secondary endpoint of overall survival. This cancer vaccine contained Agenus’ QS-21 Stimulon adjuvant. After the failure of the MAGE-A3 in melanoma last […]

Introduction The final results of the phase 1 trial of Neuralstem’s (CUR) NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) were just published in the peer-reviewed journal, Annals of Neurology. The market has responded very positively to the data with the stock up about 15% to $4.48. […]

Report In Brief This report is an in-depth analysis of Chimerix (CMRX). I like the fundamental outlook of this company very much, but I am starting coverage with a Neutral rating. The company came public in April 2013 at a price of $14.00 and was trading at about $20.00 when I began my research. At […]

This note is based on a presentation that was made by Bob Stein at the BIOCEO conference: he is the new chief medical officer of Agenus (AGEN). It was provided to paid subscribers in my note on BIO CEO highlights on February 14, 2014.  He spoke almost entirely about the recent acquisition of the privately […]

Purpose of This Report The biggest clinical trial event in all of biotechnology for 2014 could be the reporting of phase 2b results from the BENEFIT-ALS trial of tirasemtiv in ALS. This in-depth report analyzes earlier phase 1 and 2 results for tirasemtiv and how they might be predictive of a positive outcome in BENEFIT-ALS. […]

Back From BIO CEO Conference I have returned from spending two days at the BIO CEO conference at the Waldorf Astoria in New York City. Through attending presentations or one on one meetings,  I heard presentations from Advanced Cell Technology ACTC), Advaxis (ADXS), Agenus (AGEN), Alexion (ALXN) , Alkermes (ALKM), Aradigm (ARDM), Athersys (ATHX), Celator […]